This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for Sutent® (sunitinib malate) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

SUTENT

Experience that stands the test of time 

SUTENT (sunitinib malate) is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (mRCC) in adults.1​​​​​​​

Dosing

Dosing and monitoring requirements for SUTENT

More Information

Efficacy

Patient subgroups and clinical efficacy.

Learn More

Safety Profile

Important safety information and safety outcomes

See Results

SUTENT (sunitinib malate) mode of action

An introductory video to SUTENT (sunitinib malate) Mode of Action

Support for Your Patients

SUTENT (sunitinib malate) resources to support your patients including a treatment information leaflet and dosing cards

View Resources


mRCC : Metastatic Renal Cell Carcinoma​​​​​​​
PP-SUT-GBR-0664. March 2021

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No